Table 2.
Summary of immune checkpoint inhibitors and ongoing clinical trials in NKTCL patients
| Agent | Target | Trial ID | Patient number (evaluable /estimate) | Study phase | Combined agents | Indication | Results for NKTCL | References |
|---|---|---|---|---|---|---|---|---|
| Avelumab | PD-L1 | NCT03439501 | 21 | 2 | / | r/r NKTCL |
ORR: 38% CR:24% |
[60] |
| Sugemalimab (CS1001) | PD-L1 | NCT05700448 | 150 | 3 | P-GemOx | r/r NKTCL | / | / |
| Sugemalimab (CS1001) | PD-L1 | NCT03595657 | 80 | 2 | / | r/r ENKTL |
ORR:46.2%, CR:30.4% 1y OS:68.6% 2y OS:54.6% |
[61, 62] |
| IMC-001 | PD-L1 | NCT04414163 | 20 | 2 | / | r/r NKTCL | / | / |
| Camrelizumab (SHR-1210) | PD-1 | NCT03363555 | 97 | 2 | / | r/r NKTCL | / | / |
| Toripalimab | PD-1 | NCT04365036 | 207 | 3 | P-GemOx | Newly diagnosed early stage NKTCL | / | / |
| Sintilimab | PD-1 | NCT03228836 | 28 | 2 | / | r/r NKTCL |
ORR: 75.0% 1y OS:82.1% 2y OS: 78.6% |
[58] |
| Sintilimab | PD-1 | NCT04279379 | 20 | 2 | Decitabine | r/r or advanced NKTCL | / | / |
| Sintilimab | PD-1 | NCT04127227 | 63 | 2 | P-GemOx | Newly diagnosed advanced ENKTL |
ORR:100% CR:87.5% 1y OS:100% 1y PFS:95% |
[126] |
| Sintilimab | PD-1 | NCT05008666 | 37 | 2 |
Chidamide Azacitidine L-DEP |
ENKTL-HLH | / | / |
| Sintilimab | PD-1 | NCT04676789 | 30 | 2 | Pegaspargase | Limited stage NKTCL | / | / |
| Sintilimab | PD-1 | NCT03936452 | 55 | 2 |
Pegaspargase Anlotinib |
Untreated, limited stage NKTCL |
ORR:87.8% CR:87.8% 2y PFS:87.6% 2y OS:97.9% |
[127] |
| Tislelizumab | PD-1 | NCT05477264 | 38 | 2 | / | Newly diagnosed NKTCL | / | / |
| Immune Tislelizumab | PD-1 | NCT05254899 | 54 | 2 | P-GemOx | High-risk early stage ENKTL | / | / |
| Tislelizumab | PD-1 | NCT05464433 | 46 | 1/2 | Mitoxantrone hydrochloride liposome | r/r NKTCL | / | / |
| Tislelizumab | PD-1 | NCT05058755 | 62 | NA | / | r/r NKTCL | / | / |
| Tislelizumab | PD-1 | NCT04038411 | 50 | 2 | Chidamide, Lenalidomide, Etoposide | r/r NKTCL |
CR:50.0% 1y PFS:86.8% |
[76] |
| Tislelizumab | PD-1 | NCT03493451 | 77 (22 NKTCL) | 2 | / | r/r mature T- and NK-cell neoplasms |
ORR 31.8% CR 18.2% |
[128] |
| Pembrolizumab | PD-1 | NCT04417166 | 30 | 2 | / | Untreated, limited stage NKTCL | / | / |
| Pembrolizumab | PD-1 | NCT03728972 | 19 | 2 | / | Untreated, early-stage ENKTL | / | / |
| Pembrolizumab | PD-1 | NCT03107962 | 20 | 2 | / | r/r NKTCL | / | / |
| IBI318 | PD-1 and PD-L1 bispecific | NCT04602065 | 129 | 1/2 | / | r/r NKTCL | / | / |
PD-1: programmed cell death protein 1, PD-L1: programmed cell death ligand 1, NKTCL: natural killer/T-cell lymphoma, ORR: objective response rate, CR: complete remission, PR: partial remission, OS: overall survival, PFS: progression-free survival, P-GemOx: pegaspargase, gemcitabine, and oxaliplatin, ENKTL: extranodal natural killer/T-cell lymphoma, L-DEP: L-asparaginase, doxorubicin liposome, etoposide and methylprednisolone